| scholarly article | Q13442814 |
| P50 | author | David Andes | Q75205210 |
| Brian Hoff | Q79386487 | ||
| P2093 | author name string | Jeniel Nett | |
| Michelle VanHandel | |||
| Kathleen Holoyda | |||
| Karen Marchillo | |||
| Leslie Lincoln | |||
| Randall Massey | |||
| P2860 | cites work | Biofilms: survival mechanisms of clinically relevant microorganisms | Q22299328 |
| Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges | Q24625384 | ||
| Bacterial biofilms: a common cause of persistent infections | Q27861033 | ||
| The KNH1 gene of Saccharomyces cerevisiae is a functional homolog of KRE9. | Q27932092 | ||
| Sed1p is a major cell wall protein of Saccharomyces cerevisiae in the stationary phase and is involved in lytic enzyme resistance | Q27932325 | ||
| Comprehensive proteomic analysis of Saccharomyces cerevisiae cell walls: identification of proteins covalently attached via glycosylphosphatidylinositol remnants or mild alkali-sensitive linkages. | Q27933635 | ||
| A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance | Q28185783 | ||
| Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans | Q28265703 | ||
| Mechanisms of biofilm resistance to antimicrobial agents | Q29615293 | ||
| Candida biofilms: an update | Q30475833 | ||
| Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance | Q30701532 | ||
| Purified horseshoe crab factor G. Reconstitution and characterization of the (1-->3)-beta-D-glucan-sensitive serine protease cascade | Q95822316 | ||
| Candida biofilms: antifungal resistance and emerging therapeutic options. | Q30829656 | ||
| Characteristics of biofilm formation by Candida albicans. | Q31122279 | ||
| KRE5 gene null mutant strains of Candida albicans are avirulent and have altered cell wall composition and hypha formation properties | Q33559935 | ||
| Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. | Q33721804 | ||
| Candida biofilms and their susceptibility to antifungal agents | Q33766274 | ||
| Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms | Q33982871 | ||
| Cell wall and secreted proteins of Candida albicans: identification, function, and expression | Q34009982 | ||
| Identification of major glucan-associated cell wall proteins of Candida albicans and their role in fluconazole resistance | Q34109502 | ||
| Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection | Q34142971 | ||
| Candida biofilms and their role in infection | Q35044563 | ||
| Resistance of Candida albicans biofilms to antifungal agents in vitro | Q35118735 | ||
| Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols | Q35164903 | ||
| Candida infections of medical devices | Q35745818 | ||
| Biofilm formation by Candida species on the surface of catheter materials in vitro | Q35775012 | ||
| Candida albicans biofilm development, modeling a host-pathogen interaction. | Q36525072 | ||
| Mnt1p and Mnt2p of Candida albicans are partially redundant alpha-1,2-mannosyltransferases that participate in O-linked mannosylation and are required for adhesion and virulence. | Q37109793 | ||
| Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. | Q37523933 | ||
| Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. | Q39558196 | ||
| Iron-limited biofilms of Candida albicans and their susceptibility to amphotericin B | Q39559062 | ||
| In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. | Q39657947 | ||
| Penetration of Candida biofilms by antifungal agents | Q39955289 | ||
| In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models | Q40882541 | ||
| Ultrastructural Changes in the Cell Wall of Candida albicans Following Cessation of Growth and their Possible Relationship to the Development of Polyene Resistance | Q41036603 | ||
| Global control of dimorphism and virulence in fungi | Q42684204 | ||
| Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms | Q43415980 | ||
| Forging a link between biofilms and disease | Q43998783 | ||
| Survival in experimental Candida albicans infections depends on inoculum growth conditions as well as animal host | Q46611821 | ||
| Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. | Q51161653 | ||
| Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. | Q54037537 | ||
| Production of extracellular matrix by Candida albicans biofilms. | Q54144178 | ||
| Extracellular polymer of Candida albicans: isolation, analysis and role in adhesion | Q69900682 | ||
| Reduction of amphotericin resistance in stationary phase cultures of Candida albicans by treatment with enzymes | Q72153186 | ||
| Activation of limulus coagulation factor G by several (1-->3)-beta-D-glucans: comparison of the potency of glucans with identical degree of polymerization but different conformations | Q72921626 | ||
| Architecture of the yeast cell wall. Beta(1-->6)-glucan interconnects mannoprotein, beta(1-->)3-glucan, and chitin | Q73486035 | ||
| Guidelines for treatment of candidiasis | Q75213797 | ||
| A new method for quantitative determination of polysaccharides in the yeast cell wall. Application to the cell wall defective mutants of Saccharomyces cerevisiae | Q77512042 | ||
| A refined method for the determination of Saccharomyces cerevisiae cell wall composition and beta-1,6-glucan fine structure | Q77548274 | ||
| Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy | Q81739235 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Candida albicans | Q310443 |
| biofilm | Q467410 | ||
| P304 | page(s) | 510-520 | |
| P577 | publication date | 2006-11-27 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Putative role of beta-1,3 glucans in Candida albicans biofilm resistance | |
| P478 | volume | 51 |
| Q28481813 | A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance |
| Q36605876 | A common mechanism involving the TORC1 pathway can lead to amphotericin B-persistence in biofilm and planktonic Saccharomyces cerevisiae populations |
| Q33751845 | A histone deacetylase complex mediates biofilm dispersal and drug resistance in Candida albicans. |
| Q41991016 | Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species |
| Q33451098 | Activity of micafungin against Candida biofilms |
| Q35218859 | Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms |
| Q35732526 | An expanded regulatory network temporally controls Candida albicans biofilm formation |
| Q35318531 | Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model |
| Q59794490 | Antifungal and anti-biofilm activity of the first cryptic antimicrobial peptide from an archaeal protein against Candida spp. clinical isolates |
| Q37692277 | Antifungal drug resistance of oral fungi |
| Q38610742 | Application of the systematic "DAmP" approach to create a partially defective C. albicans mutant |
| Q36306851 | Assessment and Optimizations of Candida albicans In Vitro Biofilm Assays |
| Q28475655 | Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi |
| Q52579452 | Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm. |
| Q37066547 | Biofilm Exopolysaccharides of Pathogenic Fungi: Lessons from Bacteria |
| Q37392907 | Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates |
| Q38672292 | Biofilm formation in Candida glabrata: What have we learnt from functional genomics approaches? |
| Q33468384 | Biofilm matrix regulation by Candida albicans Zap1. |
| Q38120559 | Biofilm-associated infections: antibiotic resistance and novel therapeutic strategies |
| Q42663914 | Biohybrid nanostructured iron oxide nanoparticles and Satureja hortensis to prevent fungal biofilm development. |
| Q52371885 | Candida Biofilms: Threats, Challenges, and Promising Strategies. |
| Q48163282 | Candida Species Biofilms' Antifungal Resistance. |
| Q41103472 | Candida albicans Biofilm Development and Its Genetic Control. |
| Q26778729 | Candida albicans Biofilms and Human Disease |
| Q38915936 | Candida albicans Mycofilms Support Staphylococcus aureus Colonization and Enhances Miconazole Resistance in Dual-Species Interactions. |
| Q33603993 | Candida albicans Niche Specialization: Features That Distinguish Biofilm Cells from Commensal Cells |
| Q33300915 | Candida albicans Sun41p, a putative glycosidase, is involved in morphogenesis, cell wall biogenesis, and biofilm formation |
| Q40176352 | Candida albicans biofilms: comparative analysis of room-temperature and cryofixation for scanning electron microscopy. |
| Q36880010 | Candida albicans biofilms: development, regulation, and molecular mechanisms |
| Q92178533 | Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm |
| Q34747087 | Candida albicans forms biofilms on the vaginal mucosa |
| Q33693252 | Candida albicans virulence and drug-resistance requires the O-acyltransferase Gup1p |
| Q38130314 | Candida albicans, plasticity and pathogenesis |
| Q91983100 | Candida parapsilosis: from Genes to the Bedside |
| Q92156552 | Candida spp./Bacteria Mixed Biofilms |
| Q40064579 | Candidiasis and the impact of flow cytometry on antifungal drug discovery. |
| Q36729978 | Cell Wall Changes in Amphotericin B-Resistant Strains from Candida tropicalis and Relationship with the Immune Responses Elicited by the Host |
| Q42111171 | Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. |
| Q36925967 | Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance |
| Q33945417 | Characterizing the role of cell-wall β-1,3-exoglucanase Xog1p in Candida albicans adhesion by the human antimicrobial peptide LL-37. |
| Q37335095 | Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix. |
| Q35280502 | Community participation in biofilm matrix assembly and function |
| Q35653117 | Comparative analysis of Candida biofilm quantitation assays |
| Q46229761 | Contribution of the glycolytic flux and hypoxia adaptation to efficient biofilm formation by Candida albicans |
| Q89578301 | Contributions of the Biofilm Matrix to Candida Pathogenesis |
| Q46276738 | Development and regulation of single- and multi-species Candida albicans biofilms |
| Q34119405 | Development and validation of an in vivo Candida albicans biofilm denture model. |
| Q28477874 | Development of a high-throughput Candida albicans biofilm chip |
| Q35092764 | Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms |
| Q36370400 | Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study |
| Q35065709 | Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion |
| Q34399977 | Effects of salivary protein flow and indigenous microorganisms on initial colonization of Candida albicans in an in vivo model |
| Q40625328 | Efficacy of anidulafungin in the treatment of experimental Candida parapsilosis catheter infection using an antifungal-lock technique. |
| Q39207421 | Electrically conductive catheter inhibits bacterial colonization |
| Q42280529 | Enhanced antifungal activity of voriconazole-loaded nanostructured lipid carriers against Candida albicans with a dimorphic switching model |
| Q39413837 | Experimental biofilm-related Candida infections |
| Q45730982 | Expression of CgCDR1, CgCDR2, and CgERG11 in Candida glabrata biofilms formed by bloodstream isolates |
| Q39932219 | Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms. |
| Q55048944 | Fluconazole impacts the extracellular matrix of fluconazole-susceptible and -resistant Candida albicans and Candida glabrata biofilms. |
| Q53734576 | Functional analysis of selected deletion mutants in Candida glabrata under hypoxia. |
| Q36089061 | Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs |
| Q38817837 | Fungal Biofilms: Update on Resistance |
| Q91868199 | Fungal Cell Wall: Emerging Antifungals and Drug Resistance |
| Q36148245 | Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions. |
| Q38835071 | Fungal biofilm composition and opportunities in drug discovery |
| Q35821475 | Fungal biofilm resistance |
| Q34355341 | Fungal biofilms, drug resistance, and recurrent infection |
| Q41848811 | Fungal echinocandin resistance. |
| Q40676129 | Fungal β-1,3-glucan increases ofloxacin tolerance of Escherichia coli in a polymicrobial E. coli/Candida albicans biofilm. |
| Q38186068 | Future directions for anti-biofilm therapeutics targeting Candida |
| Q38786061 | Future therapies targeted towards eliminating Candida biofilms and associated infections. |
| Q49679927 | Gaining Insights from Candida Biofilm Heterogeneity: One Size Does Not Fit All. |
| Q30434904 | Genetic Basis of Antifungal Drug Resistance |
| Q33893698 | Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. |
| Q37824380 | Genetic control of Candida albicans biofilm development |
| Q34684434 | Histatin 5 resistance of Candida glabrata can be reversed by insertion of Candida albicans polyamine transporter-encoding genes DUR3 and DUR31. |
| Q36281368 | Host contributions to construction of three device-associated Candida albicans biofilms |
| Q28476836 | Hsp90 governs dispersion and drug resistance of fungal biofilms |
| Q34668042 | Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates |
| Q51532226 | Hydrodynamic effects on bacterial biofilm development in a microfluidic environment. |
| Q28483330 | Identification and characterization of antifungal compounds using a Saccharomyces cerevisiae reporter bioassay |
| Q36674558 | Identification of antifungal natural products via Saccharomyces cerevisiae bioassay: insights into macrotetrolide drug spectrum, potency and mode of action. |
| Q35798360 | Identification of novel mechanisms involved in generating localized vulvodynia pain |
| Q41711895 | Imidazolium salts as antifungal agents: strong antibiofilm activity against multidrug-resistant Candida tropicalis isolates. |
| Q36354614 | In Vitro Antifungal Activity of (1)-N-2-Methoxybenzyl-1,10-phenanthrolinium Bromide against Candida albicans and Its Effects on Membrane Integrity. |
| Q53641731 | In vitro activity of Caspofungin combined with Fluconazole on mixed Candida albicans and Candida glabrata biofilm. |
| Q41355300 | In vitro inhibitory activities of magnolol against Candida spp. |
| Q36314153 | In vitro inhibitory effects of farnesol and interactions between farnesol and antifungals against biofilms of Candida albicans resistant strains |
| Q36018571 | In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis |
| Q42681379 | Inactivation of genes TEC1 and EFG1 in Candida albicans influences extracellular matrix composition and biofilm morphology |
| Q36482736 | Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans. |
| Q57154099 | Influence of Eugenia uniflora Extract on Adhesion to Human Buccal Epithelial Cells, Biofilm Formation, and Cell Surface Hydrophobicity of Candida spp. from the Oral Cavity of Kidney Transplant Recipients |
| Q53209244 | Influence of glucose concentration on the structure and quantity of biofilms formed by Candida parapsilosis. |
| Q40335405 | Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans |
| Q38752373 | Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota |
| Q34024546 | Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents |
| Q35598281 | Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. |
| Q34237946 | Large-scale biochemical profiling of the Candida albicans biofilm matrix: new compositional, structural, and functional insights |
| Q38724208 | Management of Candida biofilms: state of knowledge and new options for prevention and eradication |
| Q26827521 | Mechanisms of Candida biofilm drug resistance |
| Q37160485 | Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi |
| Q38559208 | Medically important fungi respond to azole drugs: an update. |
| Q37124868 | Micafungin for the prophylaxis and treatment of Candida infections |
| Q40635408 | Microbial Biofilms in Pulmonary and Critical Care Diseases. |
| Q64239859 | Microevolution of the pathogenic yeasts and during antifungal therapy and host infection |
| Q38034858 | Microfluidic approaches to bacterial biofilm formation |
| Q37412802 | Molecular and cellular mechanisms that lead to Candida biofilm formation. |
| Q35175626 | Mucosal biofilms of Candida albicans |
| Q35616215 | Multiple roles for Enterococcus faecalis glycosyltransferases in biofilm-associated antibiotic resistance, cell envelope integrity, and conjugative transfer |
| Q34026267 | Novel entries in a fungal biofilm matrix encyclopedia |
| Q33843060 | Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms |
| Q38441157 | Null mutants of Candida albicans for cell-wall-related genes form fragile biofilms that display an almost identical extracellular matrix proteome |
| Q38363105 | Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies |
| Q35067093 | Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay |
| Q92808900 | Oral Candidiasis: A Disease of Opportunity |
| Q37622959 | Our current understanding of fungal biofilms |
| Q38767464 | Pathogenesis of Candida albicans biofilm |
| Q49490643 | Photodynamic Inactivation Potentiates the Susceptibility of Antifungal Agents against the Planktonic and Biofilm Cells of Candida albicans |
| Q61809091 | Physical Interaction of Sodium Houttuyfonate With β-1,3-Glucan Evokes Cell Wall Remodeling |
| Q34167894 | Portrait of Candida albicans adherence regulators |
| Q55516936 | Portrait of Matrix Gene Expression in Candida glabrata Biofilms with Stress Induced by Different Drugs. |
| Q39971235 | Preparation of Candida albicans Biofilms for Transmission Electron Microscopy. |
| Q98771311 | Promising Therapeutic Strategies Against Microbial Biofilm Challenges |
| Q30862390 | Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence |
| Q34595925 | Rat indwelling urinary catheter model of Candida albicans biofilm infection |
| Q38131290 | Recent insights into Candida albicans biofilm resistance mechanisms |
| Q36870880 | Reduced biocide susceptibility in Candida albicans biofilms |
| Q34190284 | Regulatory circuitry governing fungal development, drug resistance, and disease. |
| Q38373781 | Resistance of Candida albicans Biofilms to Drugs and the Host Immune System |
| Q33861181 | Restructuring of Enterococcus faecalis biofilm architecture in response to antibiotic-induced stress |
| Q34045325 | Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene |
| Q35667552 | Role of SFP1 in the Regulation of Candida albicans Biofilm Formation |
| Q39767233 | Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. |
| Q34643153 | Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phase |
| Q40405446 | Searching for new strategies against polymicrobial biofilm infections: guanylated polymethacrylates kill mixed fungal/bacterial biofilms. |
| Q44019485 | Silver colloidal nanoparticles: effect on matrix composition and structure of Candida albicans and Candida glabrata biofilms. |
| Q92442694 | Simple Carbohydrate Derivatives Diminish the Formation of Biofilm of the Pathogenic Yeast Candida albicans |
| Q35229804 | Site-specific mesenchymal control of inflammatory pain to yeast challenge in vulvodynia-afflicted and pain-free women |
| Q92823765 | Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical β-Peptides To Prevent Candida albicans Biofilm Formation |
| Q37122826 | Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance |
| Q37713399 | Symbiotic relationship between Streptococcus mutans and Candida albicans synergizes virulence of plaque biofilms in vivo. |
| Q59808687 | Synergistic Effect of Quinic Acid Derived From and Undecanoic Acid Against spp. Biofilm and Virulence |
| Q43063852 | Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms |
| Q51279007 | Synergistic in vitro activity of sodium houttuyfonate with fluconazole against clinical Candida albicans strains under planktonic growing conditions. |
| Q33684840 | The Candida albicans Biofilm Matrix: Composition, Structure and Function |
| Q38856993 | The Extracellular Matrix of Fungal Biofilms |
| Q26752938 | The Host's Reply to Candida Biofilm |
| Q49203638 | The Interface between Fungal Biofilms and Innate Immunity |
| Q91636108 | The Role of Candida albicans Secreted Polysaccharides in Augmenting Streptococcus mutans Adherence and Mixed Biofilm Formation: In vitro and in vivo Studies |
| Q37377912 | The Role of Isocitrate Lyase (ICL1) in the Metabolic Adaptation of Candida albicans Biofilms. |
| Q36993853 | The Susceptibility of Candida albicans to Gamma-Radiations and Ketoco-nazole Depends on Transitional Filamentation. |
| Q47388949 | The carboxylic acid transporters Jen1 and Jen2 affect the architecture and fluconazole susceptibility of Candida albicans biofilm in the presence of lactate |
| Q38009721 | The effect of biomaterials and antifungals on biofilm formation by Candida species: a review |
| Q37075845 | The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. |
| Q27026751 | The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida |
| Q35175164 | Time course global gene expression analysis of an in vivo Candida biofilm. |
| Q37728800 | Transcriptional response of Candida albicans biofilms following exposure to 2-amino-nonyl-6-methoxyl-tetralin muriate |
| Q58595410 | Transcriptomic and Genomic Approaches for Unravelling Biofilm Formation and Drug Resistance-An Update |
| Q59058044 | What Makes Oral Candidiasis Recurrent Infection? A Clinical View |
| Q54207873 | What We Do Not Know about Fungal Cell Adhesion Molecules. |
| Q51175640 | [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis]. |
Search more.